Both WHO 2022 and ICC classifications require the presence of an SF3B1 mutation (WHO: VAF ≥ 5%, ICC: VAF ≥ 10%), a bone marrow (BM) blast count <5% and the absence of certain cytogenetic abnormalities and biallelic TP53 inactivations. This evidence concerns the gene SF3B1 and intrahepatic cholangiocarcinoma.